Pfizer

Yahoo Finance • 4 days ago

Why Pfizer Inc. (PFE) is the Best Vaccine Stock to Buy According to Hedge Funds?

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best vaccine store stocks to buy now. What W... Full story

Yahoo Finance • 5 days ago

Is Pfizer Inc. (PFE) the Best Stock Under $50 to Buy Right Now?

We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now.In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks. From a certain perspective, domestic equities are o... Full story

Yahoo Finance • 5 days ago

Novavax reports large quarterly revenue declines, rethinks its strategic direction

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland, said during its earnings report that it would move... Full story

Yahoo Finance • 7 days ago

Pfizer's (NYSE:PFE) earnings have declined over three years, contributing to shareholders 34% loss

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Un... Full story

Yahoo Finance • 8 days ago

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer’s Board of Directors for potential breaches of fiduciary dutie... Full story

Yahoo Finance • 9 days ago

Prediction: These Could Be the Best-Performing Value Stocks Through 2030

Buying quality stocks when they're unpopular can be very rewarding. A good place to look for unpopular stocks these days is in the healthcare sector, as Robert F. Kennedy Jr.'s nomination and confirmation as U.S. Secretary of Health and H... Full story

Yahoo Finance • 11 days ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? On Friday, Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to com... Full story

Yahoo Finance • 14 days ago

Pfizer Inc. (PFE): Among the Best Very Cheap Stocks to Buy Right Now

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best very cheap stocks to buy right now. The stock market had a... Full story

Yahoo Finance • 18 days ago

Mark Hillman Exits Simon Property Group Inc, Impacting Portfolio by -3.28%

Insightful Moves in Hillman Capital's Fourth Quarter 2024 13F Filing Mark Hillman (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2024, providing insights into his investment moves during this period. Mark... Full story

Yahoo Finance • 19 days ago

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (m... Full story

Yahoo Finance • 20 days ago

Q4 2024 Arvinas Inc Earnings Call

Participants Jeff Boyle; Vice President of Investor Relations; Arvinas Inc John Houston; Chairman of the Board, President, Chief Executive Officer; Arvinas Inc Noah Berkowitz; Chief Medical Officer; Arvinas Inc Angela Cacace; Chief Sci... Full story

Yahoo Finance • 22 days ago

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC At nearly 30 months of follow-up... Full story

Yahoo Finance • 23 days ago

68-Year-Old Earning $4,300/Month in Dividends Shares His Top 7 Stock Picks — 'Dividends Have Been Consistent, Stable'

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. U.S. markets were seeing volatility as technology earnings began to worry investors due to soft forecasts and mounting AI-related expense... Full story

Yahoo Finance • 26 days ago

Is Pfizer Inc. (PFE) the Best Dividend Stock With 5% Yield?

We recently compiled a list of the 12 Best 5% Dividend Stocks To Buy According To Hedge Funds.In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend stocks. Dividend investors have o... Full story

Yahoo Finance • 28 days ago

Pfizer beats Q4, FY '24 earnings estimates, stock down slightly in premarket trading

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and sending the stock down about 1% in premarket trading. Pfizer reported $63.6 billion in revenue for the full ye... Full story

Yahoo Finance • 28 days ago

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 21.9% year on year to $17.76 billion. On the oth... Full story

Yahoo Finance • 28 days ago

Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance

Merck (MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance. Merck repo... Full story

Yahoo Finance • 29 days ago

Jim Cramer on Pfizer Inc. (PFE): ‘The Stock Could Soar, Very Little Downside At These Low Levels’

We recently published an article titled Jim Cramer's Game Plan: 15 Stocks in Focus.In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks featured in Jim Cramer's Game Plan. Jim Cramer... Full story

Yahoo Finance • 30 days ago

1 Stock to Buy, 1 Stock to Sell This Week: Amazon, AMD

• Trump’s trade war, U.S. jobs report, and more ‘Big Tech’ earnings will be in focus this week. • Amazon looks set to deliver strong Q4 results, driven by its cloud computing dominance and operational efficiencies, making it a strong buy.... Full story

Yahoo Finance • last month

Why Is Prem Watsa Bullish On Pfizer Inc. (PFE) Now?

We recently compiled a list of the Billionaire Prem Watsa's Top 15 Long-Term Stock Picks.In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against Prem Watsa's other long-term stock picks. Prem Watsa is a... Full story